SGL Investment Advisors Inc. Buys 138 Shares of STERIS plc $STE

SGL Investment Advisors Inc. raised its position in STERIS plc (NYSE:STE) by 1.2% during the second quarter, according to its most recent filing with the SEC. The firm owned 11,359 shares of the medical equipment provider’s stock after purchasing an additional 138 shares during the period. SGL Investment Advisors Inc.’s holdings in STERIS were worth $2,642,000 as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in STE. Geneos Wealth Management Inc. lifted its position in shares of STERIS by 416.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 129 shares of the medical equipment provider’s stock worth $29,000 after buying an additional 104 shares in the last quarter. Grove Bank & Trust lifted its stake in STERIS by 4,733.3% in the 1st quarter. Grove Bank & Trust now owns 145 shares of the medical equipment provider’s stock worth $33,000 after purchasing an additional 142 shares in the last quarter. Zions Bancorporation National Association UT bought a new position in STERIS in the 1st quarter worth about $37,000. ORG Wealth Partners LLC bought a new stake in shares of STERIS during the 1st quarter worth $43,000. Finally, Golden State Wealth Management LLC increased its position in shares of STERIS by 503.0% during the 1st quarter. Golden State Wealth Management LLC now owns 199 shares of the medical equipment provider’s stock valued at $45,000 after purchasing an additional 166 shares during the last quarter. 94.69% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. Wall Street Zen upgraded shares of STERIS from a “buy” rating to a “strong-buy” rating in a report on Sunday, September 14th. Morgan Stanley upped their target price on shares of STERIS from $276.00 to $295.00 and gave the company an “overweight” rating in a research note on Friday, August 8th. KeyCorp raised their target price on STERIS from $277.00 to $288.00 and gave the stock an “overweight” rating in a report on Tuesday, July 22nd. Finally, Weiss Ratings reaffirmed a “buy (b-)” rating on shares of STERIS in a report on Saturday, September 27th. Seven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, STERIS presently has a consensus rating of “Moderate Buy” and a consensus target price of $273.50.

Insider Activity

In other STERIS news, VP Renato Tamaro sold 3,204 shares of the business’s stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $249.24, for a total value of $798,564.96. Following the completion of the transaction, the vice president directly owned 7,221 shares in the company, valued at approximately $1,799,762.04. The trade was a 30.73% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Cynthia L. Feldmann sold 3,495 shares of the business’s stock in a transaction dated Monday, August 11th. The shares were sold at an average price of $241.56, for a total value of $844,252.20. Following the sale, the director directly owned 705 shares of the company’s stock, valued at approximately $170,299.80. This trade represents a 83.21% decrease in their position. The disclosure for this sale can be found here. Insiders sold 18,709 shares of company stock valued at $4,546,940 over the last quarter. 1.07% of the stock is currently owned by company insiders.

STERIS Trading Down 0.8%

STE stock opened at $240.58 on Tuesday. STERIS plc has a 12-month low of $200.98 and a 12-month high of $253.00. The business’s 50-day moving average is $243.36 and its 200 day moving average is $235.50. The company has a current ratio of 2.22, a quick ratio of 1.53 and a debt-to-equity ratio of 0.27. The stock has a market cap of $23.69 billion, a price-to-earnings ratio of 36.84 and a beta of 1.01.

STERIS (NYSE:STE) last posted its quarterly earnings data on Wednesday, August 6th. The medical equipment provider reported $2.34 earnings per share for the quarter, topping analysts’ consensus estimates of $2.32 by $0.02. STERIS had a net margin of 11.61% and a return on equity of 14.17%. The firm had revenue of $1.40 billion during the quarter, compared to analysts’ expectations of $1.36 billion. During the same quarter last year, the company posted $2.03 EPS. The firm’s quarterly revenue was up 8.8% on a year-over-year basis. On average, sell-side analysts anticipate that STERIS plc will post 9.08 EPS for the current fiscal year.

STERIS Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, September 26th. Shareholders of record on Thursday, September 4th were issued a dividend of $0.63 per share. This is a boost from STERIS’s previous quarterly dividend of $0.57. The ex-dividend date was Thursday, September 4th. This represents a $2.52 dividend on an annualized basis and a yield of 1.0%. STERIS’s payout ratio is currently 38.59%.

STERIS Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.